|Bid||334.55 x 800|
|Ask||335.25 x 1200|
|Day's range||320.54 - 338.53|
|52-week range||65.49 - 497.49|
|Beta (5Y monthly)||1.49|
|PE ratio (TTM)||224.42|
|Earnings date||27 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||306.31|
Shares of Moderna (NASDAQ: MRNA) were rising 3.3% as of 10:59 a.m. EDT on Monday. This gain came after the Financial Times reported new forecasts from health data analytics company Airfinity that project Moderna's COVID-19 vaccine could generate sales of $38.7 billion in 2022. Investors might be justified in jumping aboard the Moderna train if Airfinity's 2022 estimate is right.
The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.